External Pacemakers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the external pacemaker market size is expected to grow from USD 1.88 billion in 2025 to USD 1.95 billion in 2026 and is forecast to reach USD 2.35 billion by 2031 at 3.79% CAGR over 2026-2031.

This report is Segmented by Pacing Type (Transcutaneous, Transvenous (Temporary), and More), by Modality (single Chamber and Dual Chamber), End-User (Hospitals & Cardiac Centers, Ambulatory Surgical Centers, and Other More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD)

Global External Pacemakers Market Trends and Insights

Growing Volume of Cardiac & Structural-Heart Surgeries Requiring Temporary Pacing

Seventy-six percent of TAVR patients supported with a temporary generator avoid permanent devices one month later, cutting the permanent implant rate to 2.4% and saving USD 23,588 per case. This economic benefit strengthens the external pacemaker market's value proposition, particularly in cost-sensitive health systems.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Prevalence of Transient Bradyarrhythmias & CVD
2. Technological Upgrades in Dual-Chamber & Connected External Pacemakers
3. Expansion of Emergency-Medical & Ambulance Fleets Equipped with Pacing Capability
4. High Device Cost & Patchy Reimbursement
5. Infection & Lead-Related Complication Risk

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Transvenous platforms secured 37.12% of the external pacemaker market share in 2025, with capture reliability and well-established clinical familiarity. Corresponding revenue equaled roughly USD 697.9 million of the 2025 external pacemaker market size. Transcutaneous devices dominate early emergency usage, but discomfort restricts dwell time to hours. Epicardial wires remain a surgical niche yet offer definitive capture post-sternotomy. Newly branded "temporary-permanent" leads show 2.5% infection and 1.7% dislodgement rates, improving confidence for multiday support.

Demand is shifting toward systems with integrated hemodynamic sensors that report real-time capture thresholds, helping intensivists fine-tune output without fluoroscopy. Major suppliers leverage these incremental upgrades to safeguard share against cost-focused entrants, underscoring the external pacemaker market's reliance on feature innovation.

Complete Report Scope:

• By Pacing Type
  • Transcutaneous
  • Transvenous (Temporary)
  • Epicardial
  • Esophageal
• By Modality
  • Single-Chamber
  • Dual-Chamber
• By End User
  • Hospitals & Cardiac Centers
  • Ambulatory Surgical Centers
  • Emergency Medical Services
  • Military Field Hospitals
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America captured 38.12% of 2025 revenue, driven by favorable reimbursement policies, large cardiac surgery volumes, and rapid adoption of leadless platforms. AI-driven predictive analytics help U.S. centers shorten ICU dwell times, reinforcing the external pacemaker market's health-economic case. Canada advances through provincial funding adjustments that now bundle external pacing into DRG payments, while Mexico's IMSS system funds mobile coronary units equipped with transcutaneous kits.

Europe accounts for the second-largest share. France and Germany pursue sustainability by piloting device re-processing schemes that lower environmental impact without compromising sterility. The United Kingdom's NHS trials cloud dashboards for step-down unit transfer within 24 hours of lead insertion, aiming to free ICU beds. Italian and Spanish hospitals recorded a 48.2% fall in permanent implants during COVID-19 lockdowns, yet emergency pacing volumes stayed comparatively resilient.

Asia-Pacific boasts the fastest growth at 4.59% CAGR. Japan pioneered reimbursements for leadless temporary generators, and China's cath-lab count keeps multiplying in tier-2 cities. India's national ambulance upgrade program equips every vehicle with external pacing pads, broadening rural access. South Korea, Australia and Singapore contribute with ageing demographics and medical-tourism flows that rely on quick-turnaround cardiac procedures to fuel the external pacemaker market.

Latin America and the Middle East & Africa remain nascent yet promising. Brazil's SUS is piloting unit-price caps to stimulate local assembly, while Saudi Arabia funds advanced cardiac centers under Vision 2030. These programs could accelerate adoption once staff training and supply-chain barriers ease.

1. Medtronic
2. Abbott Laboratories
3. Boston Scientific
4. BIOTRONIK
5. Osypka Medical
6. Zoll Medical
7. Stryker (Physio-Control)
8. Pacetronix
9. Cook Group
10. Lepu Medical
11. MicroPort CRM
12. LivaNova
13. Shree Pacetronix
14. Oscor
15. Inomed Medizintechnik
16. Shenzhen Mindray Bio-Medical
17. Nihon Kohden
18. Fukuda Denshi
19. Vector Medical
20. BIOTRONIK

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support